Eli Lilly and Co (LLY) Cowen's 44th Annual Health Care Conference (Transcript)

Eli Lilly and Co (NYSE:LLY) Cowen's 44th Annual Health Care Conference March 6, 2024 9:10 AM ET

Company Participants

Anat Ashkenazi - EVP & CFO
Andrew Adams - Vice President of New Therapeutic Modalities & Scientific Leader

Conference Call Participants

Stephen Scala - TD Cowen

Anat Ashkenazi

Thank you all for coming to listen to the Lilly’s story this morning, and hope I'm sure you've been tracking us for a while. And you've seen what we've shared on the earnings call, the great progress we've had last year and that we're continuing to have robust top-line growth driven by our key growth products. And as we've shared for guidance for the year, at the midpoint, we're going to be growing at 20%.

And since then, since the call, we launched our KwikPen, Mounjaro KwikPen in the U.K. So that's an exciting start to patients in the U.K. We saw the MASH or NASH data for tirzepatide, which was incredibly exciting. But we also have always in our business, sometimes there are setbacks, we've announced the CYCLONE 2 for Verzenio prostate cancer did not meet the endpoint, and we terminated CYCLONE 3 as well.

So, we -- and entering here, and I'm sure you'll have questions for him on our Lp(a) program that initiated Phase III as well as retatrutide, where we're expanding and initiated Phase III in type 2 diabetes. So, we're really progressing across every part of our core therapeutic areas, and Lilly is showing meaningful progress in our pipeline as well as our commercial products and global presence as well. So, we're excited with where we are and excited to be here with you today and answer any questions you might have.

Stephen Scala

So, a lot to talk about, obviously, in this session. Should you have a question anywhere along the